Eli Lilly Applies For Emergency Approval For Covid-19 Antibodies


The US biotech firm Eli Lilly on Wednesday announced it was seeking an emergency use authorization (EUA) for its lab-produced antibody treatments against Covid-19, after early trial results showed they reduced viral load, symptoms and hospitalization rates.

“Our teams have worked tirelessly the last seven months to discover and develop these potential antibody treatments,” said Daniel Skovronsky, Lilly’s chief scientific officer.

“Lilly is diligently working with regulators around the world to make these treatments available,” he added.

The company said in a statement that its “combination therapy” of two antibodies working together was shown to be effective in a placebo-controlled study of 268 patients with mild to moderate Covid-19.

Their analysis showed the proportion of patients with high viral load at day 7 of their illness was 3.0 percent on the therapy, compared to 20.8 percent on the placebo arm.

Improvement in symptoms was seen as early as three days after dosing.

The rate of Covid-related hospitalization and emergency visits was 0.9 percent for patients treated with combination therapy versus placebo 5.8 percent on placebo, a relative risk reduction of 84.5 percent.

The company is also studying a “monotherapy” of just one of the two antibodies, and said that parallel research showed that this was similarly effective.

The trial is ongoing and Lilly wants to recruit a total of 800 people.

Lilly said it expects to have 100,000 doses of the monotherapy available this month, and a million by the end of the year. It also expects to have 50,000 doses of the combination therapy by the end of 2020.

The findings have not yet been published in a peer-reviewed journal.

Both antibodies work by binding to different parts of spike proteins on the surface of the SARS-CoV-2 virus, distorting their structure so the virus can’t invade living cells.

Antibodies are infection-fighting proteins made by the immune system and can also be harvested from recovered patients, but it is not possible to make so-called “convalescent plasma” a mass treatment.

Researchers can also comb through the antibodies produced by recovered patients and select the most effective out of thousands, and then manufacture them at scale.

US President Donald Trump, who has Covid-19, received a dose of synthetic antibodies produced by the firm Regeneron last week.

Regeneron has also reported encouraging results from its early trials, but hasn’t yet applied for emergency approval and so remains an experimental treatment.

The US Food and Drug Administration has previously granted an EUA for the antiviral remdesivir, for convalescent plasma, and for hydroxychloroquine, which was subsequently revoked over safety fears.

In addition, US health authority’s guidelines recommend the use of the steroid dexamethasone to control a damaging inflammatory response seen in later stages of Covid-19.





Source link

Brady relieved to be facing Peyton, not Eli, in golf match



FILE PHOTO: New England Patriots quarterback Tom Brady speaks at a press conference ahead of Super Bowl LIII in Atlanta, Georgia, U.S., January 31, 2019. REUTERS/Mike Segar/File Photo

May 12, 2020

Tom Brady traditionally got the better of fellow quarterback Peyton Manning during their encounters on the gridiron, however the latter’s family holds a 2-0 edge in head-to-head Super Bowl tilts.

Perhaps it was with that in mind that Brady offered the following response when asked if he was sick of defeating Peyton Manning ahead of “The Match: Champions for Charity” golf event on May 24:

“No, you kidding me? Eli’s the one that I’m actually happy I’m not playing,” Brady said on the Stupodity podcast.

While Brady posted an 11-6 record against Peyton Manning in head-to-head encounters, Eli Manning captured Super Bowl MVP honors on two occasions after thwarting Brady in the final game of the playoffs.

Eli Manning led the New York Giants to a 17-14 victory over Brady’s former team, the New England Patriots, in Super Bowl XLII during the 2007 season. He also guided the Giants to a 21-17 win over the Patriots in Super Bowl XLVI to finish the 2011 campaign.

Peyton Manning will team with Tiger Woods against Brady and Phil Mickelson at “The Match: Champions for Charity,” which will tee off at the Medalist Golf Club in Hobe Sound, Fla. The event will raise $10 million for COVID-19 relief and will be played without fans in attendance.

–Field Level Media





Source link